🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against superbug strains of the infection, according to health experts.

An International Challenge

The sexually transmitted infection are escalating around the world, with figures suggesting more than 82 million instances annually. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the context of rising global incidence, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Medical experts are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

Zoliflodacin, also known as a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts hope that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This treatment, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This milestone marks a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Testing Results and Global Access

According to data published in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which uses two antibiotics. The trial involved nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to license and sell the drug in numerous developing nations.

Clinicians directly involved have shared positive views. The availability of a single-dose, oral treatment of this kind is hailed as a "critical tool" for public health efforts. This is deemed essential to lessen the impact of the disease for patients and to halt the transmission of untreatable gonorrhoea around the world.